A panel of autoantibodies that are progressively up-regulated could be potentially used as predictive biomarkers for the progression of primary SS to mucosa-associated lymphoid tissue (MALT) lymphoma [67], while calcium‐binding proteins S100A8/A9 levels in parotid saliva (and not whole saliva) were found to be discriminatory for SS patients with lymphoma or at higher risk of lymphoma [68]. This evidence concerns the gene IGKV1D-22 and synovial sarcoma.